CN115337335A - 一种具有抗糖化功效的桑葚提取物的制备方法及其应用 - Google Patents
一种具有抗糖化功效的桑葚提取物的制备方法及其应用 Download PDFInfo
- Publication number
- CN115337335A CN115337335A CN202210999821.5A CN202210999821A CN115337335A CN 115337335 A CN115337335 A CN 115337335A CN 202210999821 A CN202210999821 A CN 202210999821A CN 115337335 A CN115337335 A CN 115337335A
- Authority
- CN
- China
- Prior art keywords
- mulberry
- extract
- preparation
- mulberry extract
- water bath
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 91
- 240000000249 Morus alba Species 0.000 title claims abstract description 91
- 239000000284 extract Substances 0.000 title claims abstract description 90
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000000463 material Substances 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims description 18
- 108090000604 Hydrolases Proteins 0.000 claims description 17
- 108010059820 Polygalacturonase Proteins 0.000 claims description 16
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 241000194108 Bacillus licheniformis Species 0.000 claims description 4
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 230000003064 anti-oxidating effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 25
- 235000013399 edible fruits Nutrition 0.000 abstract description 12
- 235000015203 fruit juice Nutrition 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 45
- 239000000243 solution Substances 0.000 description 34
- 239000006228 supernatant Substances 0.000 description 17
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 16
- 229940118019 malondialdehyde Drugs 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 102000004157 Hydrolases Human genes 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 235000011869 dried fruits Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- -1 ABTS radical Chemical class 0.000 description 8
- 239000005715 Fructose Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 229960002591 hydroxyproline Drugs 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000006286 aqueous extract Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000218231 Moraceae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000010178 pectin extract Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- POLBLONFVZXVPI-UHFFFAOYSA-N N-methyl-sec-pseudobrucine Natural products O=C1CC2C3C(CC4=O)OCC=C2CN(C)CCC11C3N4C2=C1C=C(OC)C(OC)=C2 POLBLONFVZXVPI-UHFFFAOYSA-N 0.000 description 2
- FLBVMURVUYAZMG-UHFFFAOYSA-N Novacin Natural products CN1CCC23C4C5C(CC(=O)N4c6cc(C)c(C)cc26)OCC=C(C1)C5CC3=O FLBVMURVUYAZMG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102100034283 Annexin A5 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有抗糖化功效的桑葚提取物的制备方法,包括以下步骤:(1)取桑葚材料加入至水中进行水浴加热;(2)水浴加热完成后,再进行离心取上清液,得到桑葚提取物。本发明通过对桑葚果干、果渣和果汁原料的筛选及工艺优化,引入热水/热水+酶辅助的提取工艺,不仅提升了提取物的得率,同时通过体外、细胞和动物实验验证了其抗糖化功效。
Description
技术领域
本发明涉及植物提取技术领域,具体的说涉及一种具有抗糖化功效的桑葚提取物的制备方法及其应用。
背景技术
桑葚是桑科植物桑MorusalbaL.的果穗,在我国作为水果食用和中药使用的历史非常悠久,我国桑的栽培已有几千年的历史,是世界上最早利用桑叶养蚕的国家,我国桑的种植分布也很广,在利用桑叶养蚕时人们就已经开始食用桑葚。《唐本草》中记载其:“单食,主消渴”,《本草经疏》中记载其:“利五脏、解中酒毒、利水气而消肿”,《本草纲目》中记载其对“水肿胀满、瘰疬结核”的应用。桑葚除了含有丰富的维生素、微量元素、氨基酸等营养成分之外,现代成分分析表明,桑葚主要含有多酚和多糖二大类功能性化合物,这些功能性成分具有抗氧化、抗肿瘤、降血糖和降血脂等功效。随着大健康产业的蓬勃发展,桑葚提取物功能性研究不断深入,人们对与桑葚提取物在不同功能方面的作用更加重视。
还原糖的羰基和多肽、蛋白质等分子的自由氨基可发生非酶反应形成一系列复杂的化合物。主要包括具有荧光光谱特性且互相交联的化合物,例如戊糖素(Pentosidine);不具有荧光光谱特性但结构上互相交联的化合物,例如Glyoxalderivedlysinedimer(GOLD);以及既无荧光光谱特性也无结构交联的化合物,例如羧甲基赖氨酸(Nε﹣(carboxymethyl)lysine,CML)。这些由羰基和氨基在美拉德反应末期形成的结构复杂的化合物统称为AGEs。多项研究已经证实,在食品热加工过程(食源性)和人体环境(内源性)中均可形成AGEs,并且这些AGEs可在人体内长期积累。AGEs在器官、组织和循环系统中的过量积累,可通过与其特有的受体(Receptorforadvancedglycationendproducts,RAGE)结合或是加重机体的氧化应激状态和炎症反应等多种途径诱发或加剧衰老、糖尿病、动脉粥样硬化、阿尔兹海默症等疾病,具有不可忽视的生理毒性。
目前桑葚提取物在抗糖化功效方面的研究较少,其具体的作用机理及应用更是鲜少报道。
因此,提供一种具有抗糖化功效的桑葚提取物的制备方法及应用是本领域技术人员亟需解决的技术问题。
发明内容
有鉴于此,本发明提供了一种具有抗糖化功效的桑葚提取物的制备方法。
为了实现上述目的,本发明采用如下技术方案:
一种具有抗糖化功效的桑葚提取物的制备方法,包括以下步骤:
(1)取桑葚材料加入至水中进行水浴加热;
(2)水浴加热完成后,再进行离心取上清液,得到桑葚提取物。
进一步,步骤(1)中所述桑葚材料为桑葚干果、桑葚汁或桑葚果渣。
进一步,步骤(1)中所述桑葚材料与水的质量比为5:1-1:20。
采用上述进一步方案的有益效果在于:将桑葚材料与上述比例水混合能够提高桑葚材料的提取效率。
进一步,所述步骤(1)中还包括桑葚材料加入至水中后再加入酶,50℃酶解2h后,再进行水浴加热。
更进一步,所述酶为果胶酶或植物水解酶;
优选的,所述果胶酶为购买自诺维信的pectine XXL,所述植物水解酶为购买自诺维信的ViscozymeL;
所述酶的加入原料量为桑葚材料质量的0.05-0.2%。
采用上述进一步方案的有益效果在于:在本发明限定的浓度添加量下,桑葚原料具有更好的提取率和抗糖化功效。
进一步,所述步骤(1)的操作为:将桑椹材料介入含有枯草芽孢杆菌、地衣芽孢杆菌和乳酸菌的发酵种子液,45-60℃发酵20-25小时,发酵结束后保持温度为45-60℃,每隔5h搅拌一次,发酵完成后加入果胶酶或植物水解酶酶解0.5-5h,再进行水浴加热。
更进一步,所述发酵种子液中枯草芽孢杆菌活菌数为1-5×1011CFU/g;
发酵种子液中地衣芽孢杆菌活菌数为1-5×1011CFU/g;
发酵种子液中乳酸菌加入量为活菌数为1-5×1011CFU/g;
所述桑椹材料与发酵种子液的质量比为1:2-4。
进一步,步骤(1)中所述水浴温度为70-75℃,水浴时间为4-6h,震荡速率为100-300r/min。
进一步,步骤(2)中所述离心速率为6000-10000r/min,离心时间为10-30min。
采用上述进一步方案的有益效果在于:通过本发明的上述离心操作能够充分分离酶解提取液中可溶和不可溶物质。
本发明的有益效果在于:本发明通过对桑葚果干、果渣和果汁原料的筛选及工艺优化,引入热水/热水+酶辅助的提取工艺,不仅提升了提取物的得率,同时通过体外、细胞和动物实验验证了其抗糖化功效。
附图说明
图1为不同提取方式提取率对比;
图2为不同提取方式桑葚提取物总酚含量;
图3为不同提取方式桑葚提取物抗氧化能力;
图4为不同提取方式桑葚提取物对MGO体系的抗糖化能力;
图5为不同提取方式桑葚提取物对果糖体系的抗糖化能力;
图6为不同提取方式桑葚提取物对MGO诱导的HaCaT角质成形细胞损伤的保护作用-细胞存活率结果;
图7为不同提取方式桑葚提取物对MGO诱导的HaCaT角质成形细胞损伤的保护作用-流式细胞仪结果;
图8为不同提取方式桑葚提取物对受损细胞中SOD活力的影响;
图9为不同提取方式桑葚提取物对受损细胞中MDA含量的影响;
图10为不同提取方式桑葚提取物对衰老鼠皮肤中水分含量(A)、透明质酸(B)和羟脯氨酸(C)含量的影响;
图11为不同提取方式桑葚提取物对衰老鼠血清中谷胱甘肽过氧化物酶含量(A)、MDA含量(B)和SOD活力(C)的影响;
图12为不同提取方式桑葚提取物对衰老鼠皮肤糖基化终产物(AGEs)的影响。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
果干水提物:称取20g桑葚果干,加入200mL蒸馏水和转子,在70℃热水浴中提取6h,震荡速率为180r/min,结束后离心取上清,记为DMF-W。
实施例2
果干植物水解酶辅助提取物:称取20g桑葚果干,加入200mL蒸馏水,加入0.02g植物水解酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为DMF-H。
实施例3
果干果胶酶辅助提取物:称取20g桑葚果干,加入200mL蒸馏水,加入0.02g果胶酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为DMF-P。
实施例4
果汁水提物:称取20g桑葚果汁,加入200mL蒸馏水,在70℃热水浴中提取6h,震荡速率为180r/min,结束后离心取上清,记为MJ-W。
实施例5
果汁植物水解酶辅助提取物:称取20g桑葚果汁,加入200mL蒸馏水,随后加入0.02g植物水解酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为MJ-H。
实施例6
果汁果胶酶辅助提取物:称取20g桑葚果汁,加入200mL蒸馏水,加入0.02g果胶酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为MJ-P。
实施例7
果渣水提物:称取20g桑葚果渣,加入200mL蒸馏水,在70℃热水浴中提取6h,震荡速率为180r/min,结束后离心取上清,记为MFP-W。
实施例8
果渣植物水解酶辅助提取物:称取20g桑葚果渣,加入200mL蒸馏水,加入0.02g植物水解酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为MFP-H。
实施例9
果渣果胶酶辅助提取物:称取20g桑葚果渣,加入200ml蒸馏水,加入0.02g果胶酶,50℃水浴酶解2h后,升温至75℃水浴4h,结束后离心取上清,记为MFP-P。
试验例1
测定不同提取方式提取率,结果如图1所示。由图1可知不同原料及不同提取方法提取物得率差别较大。其中,果干因其水分含量低,所以其提取物得率显著高于其他两种原料(果渣、果汁)。而使用水提法直接提取6h所得到的得率最高,为73.05%(DMF-W),其次是果胶酶酶解2h后继续升温提取4h,提取率为57.05%(DMF-P),而植物水解酶的提取率为最低(38%)。
试验例2
测定不同提取方式桑葚提取物总酚含量,结果如图2所示。由图2可知,总酚含量从高到低依次是果干植物水解酶辅助提取物(DMF-H)>果干水提物(DMF-W)果干果胶酶辅助提取物(DMF-P)>果渣水提物(MFP-W)>果渣植物水解酶辅助提取物(MFP-H)>果渣果胶酶辅助提取物(MFP-P)>果汁提取物三个样品。综上,果干及果渣提取物的总酚含量均较高。
试验例3ABTS自由基清除能力
利用75mmol/L的磷酸盐缓冲溶液(pH=7.4)将空白对照组在734nm处的;吸光值调整0.70±0.02。然后将所有桑葚提取物溶液由pH7.4的75M磷酸盐缓冲液稀释至其吸光值为0.70±0.02;在96微孔板中加入50μl桑葚提取物溶液,然后用移液器加入150μlABTS自由基溶液中。反应混合液在30℃下保温30min,测定其在734nm处的吸光值,计为Asample。时间为30min,每隔5min采集一次数据。最终结果采用由Trolox当量μMTE/g抗氧化物表示。结果如图3所示。
ABTS的储备溶液配置为:取2.45mM的过硫酸钾溶液和7mMABTS溶液按1:1比例混匀,并于常温黑暗下保存12-16小时,充分发生氧化还原反应后制备得到形成储备液。
由图3可知,各提取物组间ABTS自由基清除能力差异较大,其中果渣提取物的自由基清除能力≥果干提取物自由基清除能力>果汁提取物清除能力。且水提物的自由基清除能力较其他两种方式更强。这与总酚含量呈现部分相关性。
试验例4
4.1BSA-MGO模拟反应体系的建立
先将用不同方法提取的桑葚提取物溶液(0.1mg/ml)取1ml分别与1ml丙酮醛溶液(60mmol/L)混合,在37℃培养箱中孵育2h,然后加入1mlBSA溶液(30mg/ml)。阳性对照方采用相同质量浓度的氨基胍替换桑葚提取物溶液进行;空白对照采用磷酸缓冲液替换桑葚提取物溶液进行;磷酸盐缓冲液替代MGO溶液作为BSA单独孵育组和BSA-桑葚提取物共孵育组。将混合以后的样品置于培养箱中37℃孵育6天。在分析前,用160μl0.2M磷酸盐缓冲液(pH7.4)将40μl的牛血清白蛋白-丙酮醛溶液稀释5倍,然后转移到96孔黑色荧光读数板上。在激发波长370nm和发射波长440nm的条件下测定样品的荧光强度(在激发波长340nm和发射波长435nm下进行监测糖化产物的荧光强度—果糖。)。不同方式提取的桑葚提取物,对最大荧光活性AGEs所产生的最大抑制效应R按照下述式计算。结果如图4所示。
其中,FA为个样品组的荧光强度;FB为空白组的荧光强度。
由图4所示,不同样品MGO-BSA体系抗糖化能力对比结果可知,所有样品抗糖化能力均较高,高于阳性对照氨基胍的抗糖化能力,其中果干水提物(DMF-W)的抗MGO诱导的糖基化能力>果干果干果胶提取物(DMF-P)>果渣植物水解酶辅助提取物(MFP-H)>果渣果胶酶辅助提取物(MFP-P)>果汁植物水解酶辅助提取物(MFP-H)。
4.2BSA-果糖模拟反应体系的建立
将不同方法提取的桑葚提取物溶液(0.1mg/ml)1ml分别与1ml果糖溶液(1.5mol/L)混合,37℃孵育2h。后将1mlBSA溶液(30mg/ml)加入其中。阳性对照使用同质量浓度的氨基胍替代桑葚提取物溶液进行;空白对照使用磷酸缓冲液替代桑葚提取物溶液进行;磷酸缓冲液替代果糖溶液作为BSA单独孵育组和BSA-桑葚提取物共孵育组。将混合以后的样品置于培养箱中37℃孵育6d后,在激发波长370nm和发射波长440nm的条件下测定桑葚样品的荧光强度。使用不同方法提取的桑葚提取物溶液对荧光性AGEs生成的抑制率R由下面公式计算。结果如图4所示。
其中,FA为个样品组的荧光强度;FB为空白组的荧光强度。
由图5所示,不同提取物样品对果糖BSA体系抗糖化能力的对比结果差异较大,其中各组中果胶酶辅助提取的提取物抗果糖糖化能力均强于植物水解酶辅助提取物且强于水提物。所有提取物的抗果糖糖化能力均强于阳性对照氨基胍。其中,果干果胶酶辅助提取物(DMF-P)对果糖糖基化抑制能力达到76.02%,大于果渣果胶酶辅助提取(75.33%)。
试验例5
在细胞贴壁面积满90%或以上时,可用一次性的塑料吸管或移液枪吸取培养瓶内的原有细胞培养基,用PBS水溶液冲洗两到三遍。加入1ml含有0.25%胰蛋白酶消化液的DMEM培养基,放入培养箱中消化三至四分钟。显微镜观察,当细胞因收缩而变为球形并在瓶壁松动后,再注入两毫升的完全培养基以终止消化。用一次性塑料吸管多次吹击培养瓶瓶壁,使贴壁细胞自瓶壁脱离形成均匀而分散的细胞悬液。将细胞悬液汇集在十五毫升的离心管中,,置于离心机1000rpm离心三分钟,去除上清液并收集细胞沉淀。细胞冻存法则向细胞沉淀中加入比例为九比一的胎牛血清和DMSO溶液配制成的细胞冻存液,吹打重悬,把细胞悬液用吸管抽到冻存管中,然后密封,做好标记,放入预冷的冻存盒中。细胞传代法则将从细胞沉淀中掺入完全培养基,吹打均匀,在装有新完全培养基的培养瓶内加入三分之一的细胞悬液,混匀,做好标记。将培养瓶放回含5%CO2,在37℃的恒温培养箱中继续生长培养。
HaCat细胞在0.05mg/ml时的存活率:孵育HaCat细胞至每个孔内细胞约占75%时,在96孔板中加入浓度为0.05mg/ml的桑葚提取物溶液并孵育24小时。继续向培养板中加入100ul含有不同浓度的MGO溶液或桑葚提取物溶液的培养液并孵育24小时后,加10ulCCK-8溶液,并于培养箱中孵育4小时。用酶标仪得出在450nm处的吸光值。细胞存活率用T/C%表示。
HaCat细胞在0.1mg/ml时的存活率:孵育HaCat细胞至每个孔内细胞约占75%时,在96孔板中加入浓度为0.1mg/ml的桑葚提取物溶液并孵育24小时。继续向培养板中加入100ul含有不同浓度的MGO溶液或桑葚提取物溶液的培养液并孵育24小时后,加10ulCCK-8溶液,并于培养箱中孵育4小时。用酶标仪得出在450nm处的吸光值。细胞存活率用T/C%表示。结果如图6所示。
由图6所示,不同提取物样品对细胞的保护作用由损伤后细胞存活率显示。其中MFP-W,MFP-H,DMF-P等样品具有显著的保护效果MFP-P和DMF-W也具有较好的保护效果,因此结合体外抗糖化、抗氧化实验,选取果干水提物(DMF-W)和果干果胶提取物(DMF-P)进行接下来的实验。
试验例6
HaCaT细胞胰酶消化后调整细胞密度为5×103/ml在6孔板孵育12小时。细胞板移除旧培养液,消化重悬处理后细胞,500μl的PBS内加入5μl的FITC标记的Annexin-V和5μl的propidiumiodide(PI)染色15分钟,应用流式细胞仪检测,并用FlowJo分析数据。结果如图7和表1所示。
表1流式细胞仪分析样品对MGO-损伤的HACAT细胞的保护作用
由表1和图7可知,流式细胞仪不同象限代表细胞的状态不同,与正常组相比,模型组的活细胞数量显著降低,早期凋亡及晚期凋亡、已坏死细胞显著增加。而经过不同样品处理之后,在不同阶段细胞均有改善效果。其中果干果胶对活细胞、早期凋亡细胞、晚期凋亡坏死细胞及已坏死细胞的改善作用优于其他组别,甚至好于阳性对照组。其中DMF-P效果最好,尤其是在活细胞和早期凋亡细胞比率方面有显著改善效果。
试验例7细胞中SOD活力的测定
使用的方法为黄嘌呤氧化酶法,当被测样品中含SOD时,SOD能促进过氧阴离子歧化,使亚硝酸盐的生成减少,这样当进行比色试验时,在测定管内所表达的吸收光度值相较对照组将显著减少,随后运用公式可推算出所测样本里SOD活力。
按照说明书提前配置试剂,配置完成后开始实验。
超声破碎:在细胞沉淀中加入一定量的PBS,功率300W,冰水浴,每3-5秒超声一次,间隔4次。样品超声后,样品超声后,取出96孔板并设置对照孔、对照空孔、测定孔、试验空孔,按照表2加入试剂。
表2 SOD测定的配制
对照孔 | 对照空白孔 | 测定孔 | 测定空白孔 | |
待测样品(ul) | - | - | 20 | 20 |
蒸馏水(ul) | 20 | 20 | - | - |
酶工作液(ul) | 20 | - | 20 | - |
酶稀释液(ul) | - | 20 | - | 20 |
底物应用液(ul) | 200 | 200 | 200 | 200 |
混匀,在37℃下孵育约20min,并得出酶标仪设置为450nm时的吸光值。
结果如图8所示。
根据图8可知,细胞损伤会导致其氧化应激水平的改变,由前期研究结果显示,样品处理后细胞中活性氧呈现不同程度的下降。为进一步探明原因,本技术对细胞内超氧化物歧化酶SOD的活力进行检测,研究结果发现,与正常组相比Model组的超氧化物歧化酶活力显著下降,而与模型组相比,所有处理组别均能够显著提升受损细胞的SOD活力,其中果干果胶提取物(DMF-P)改善提升SOD活力的能力最强,其次是阳性对照氨基胍,紧接着是果干水提物组(DMF-W)。由结果可知,DMF-P可以通过改善SOD活力,从而实现改善细胞氧化应激状态的目的。这可能有助于DMF-P改善细胞糖化损伤。
试验例8细胞中MDA含量的测定
机体通过酶系统与非酶系统产生氧自由基,后者能攻击生物膜中的多不饱和脂肪酸,引发脂质过氧化作用,并因此形成脂质过氧化物。如:醛基(丙二醛MDA)、酮基、羟基、羰基、过氧化氢或内过氧基,以及新的氧自由基等。脂质过氧化作用不仅把活性氧转化成活性化学剂,即非自由基性的脂类分解物,而且通过链式或链式支链反应,放大活性氧的作用。因此,初始的一个活性氧能导致很多脂类分解产物的形成,这些分解产物中,一些是无害的,另一些则能引起细胞代谢及功能障碍,甚至死亡。氧自由基不但通过生物膜中多不饱和脂肪酸的氧化引起细胞损伤,而且还能通过酯氢过氧化物的分解产物因其细胞损伤。因而测试MDA的量常常可反映机体内脂质过氧化的程度,简介地反映出细胞损伤的程度。过氧化脂质降解产物中的MDA可与硫代巴比妥酸(TBA)缩合形成红色产物,在532nm出有最大吸收峰。根据试剂盒说明进行试验并测定细胞中MDA的值。结果如图9所示。
生物体内,自由基作用于脂质发生过氧化反应,氧化产物最终为丙二醛(MDA),会引起蛋白质、核酸等生命大分子的交联聚合,且具有细胞毒性。因此,改善机体MDA水平,也是实现抗氧化、抗糖化保持细胞活力的重要手段之一。由图9结果可知,与正常组相比,模型组MDA含量显著上升,随着样品组的处理,MDA含量显著下降,其改善效果由高到低依次是:果干果胶(DMF-P)>果干水提物(DMF-W)>氨基胍(阳性对照)。由此可知,样品能够通过改善MDA而实现改善细胞状态。
试验例9
构建D-半乳糖诱导的小鼠衰老模型,分别从皮肤含水量、透明质酸和羟脯氨酸含量,血清和组织AGEs、氧化应激水平等,评估样品抗糖化水平。
9.1测试不同提取方式桑葚提取物对衰老鼠皮肤中水分含量、透明质酸和羟脯氨酸含量的影响,皮肤中水分含量、透明质酸和羟脯氨酸含量是显示其皮肤状态的重要指标。由图10A可知,模型鼠与正常组相比,其水分含量显著下降(P<0.05),而DMF-W处理组和DMF-P处理组均可显著提升其皮肤中水分含量,其中DMF-P效果更好(P<0.001)。由图10B可知,模型鼠与正常组相比,其透明质酸含量显著下降(P<0.05),而DMF-P处理组别可显著提升衰老鼠皮肤中透明质酸含量(P<0.01),DMF-W组也可提升皮肤中HA含量。由图10C可知,虽然模型组中羟脯氨酸含量并没有显著低于正常组,但是DMF-W和DMF-P组别均可一定程度提升皮肤中羟脯氨酸含量,其中DMF-P组可显著提升其羟脯氨酸含量(P<0.05)。
9.2处理组别血清抗氧化体系的变化也可反应样品在衰老模型鼠体内的抗氧化能力。由图11A可知,与正常组相比,模型鼠血清中GSH-PX含量显著下降,而两个处理组别均可提升其血清GSH-PX含量,其中DMF-P组别的提升效果较为显著。由图11B可知,与正常组相比,模型鼠血清中MDA含量显著上升,而两个处理组别均可显著下调其血清MDA含量。由图11C可知,与正常组相比,模型鼠血清中SOD活力显著下降,而两个处理组别均可显著提升其血清SOD活力,其中DMF-W组别效果较好。因此,两个样品均可显著改善衰老鼠体内氧化应激损伤。
9.3皮肤AGEs指标可反应皮肤糖基化水平,采用Elisa试剂盒测定各处理组别中小鼠皮肤中糖基化终产物含量。由图12可知,与正常组相比,模型组皮肤中AGEs含量显著升高,由此说明D半乳糖所致衰老模型可导致皮肤糖基化水平升高。而处理组别均可显著降低衰老模型鼠皮肤中的糖基化终产物AGEs,其中DMF-P的降低效果较为明显。由此可知,本技术所得到的桑葚提取物具有体内和体外抗糖化功效。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (10)
1.一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,包括以下步骤:
(1)取桑葚材料加入至水中进行水浴加热;
(2)水浴加热完成后,再进行离心取上清液,得到桑葚提取物。
2.根据权利要求1所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,步骤(1)中所述桑葚材料为桑葚干果、桑葚汁或桑葚果渣。
3.根据权利要求1所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,步骤(1)中所述桑葚材料与水的质量比为5:1-1:20。
4.根据权利要求1所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,所述步骤(1)中还包括桑葚材料加入至水中后再加入酶,45-60℃酶解0.5-5h后,再进行水浴加热。
5.根据权利要求4所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,所述酶为果胶酶、植物水解酶;
所述酶的加入桑葚材料质量的0.05-0.2%。
6.根据权利要求5所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,所述步骤(1)的操作为:将桑椹材料介入含有枯草芽孢杆菌、地衣芽孢杆菌和乳酸菌的发酵种子液,45-60℃发酵20-25小时,发酵结束后保持温度为45-60℃,每隔5h搅拌一次,发酵完成后加入果胶酶或植物水解酶酶解0.5-5h,再进行水浴加热。
7.根据权利要求6所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,所述发酵种子液中枯草芽孢杆菌活菌数为1-5×1011CFU/g;
发酵种子液中地衣芽孢杆菌活菌数为1-5×1011CFU/g;
发酵种子液中乳酸菌加入量为活菌数为1-5×1011CFU/g;
所述桑椹材料与发酵种子液的质量比为1:2-4。
8.根据权利要求1所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,步骤(1)中所述水浴温度为70-75℃,水浴时间为4-6h,震荡速率为100-300r/min。
9.根据权利要求1所述一种具有抗糖化功效的桑葚提取物的制备方法,其特征在于,步骤(2)中所述离心速率为6000-10000r/min,离心时间为10-30min。
10.根据权利要求1-9任一项所述方法制备的桑葚提取物在制备抗糖化、抗氧化的药物、食品或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210999821.5A CN115337335A (zh) | 2022-08-19 | 2022-08-19 | 一种具有抗糖化功效的桑葚提取物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210999821.5A CN115337335A (zh) | 2022-08-19 | 2022-08-19 | 一种具有抗糖化功效的桑葚提取物的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115337335A true CN115337335A (zh) | 2022-11-15 |
Family
ID=83953594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210999821.5A Pending CN115337335A (zh) | 2022-08-19 | 2022-08-19 | 一种具有抗糖化功效的桑葚提取物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115337335A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924350A (zh) * | 2017-04-07 | 2017-07-07 | 龙文杰 | 一种桑葚提取物及其制备方法和应用 |
CN109939051A (zh) * | 2019-04-25 | 2019-06-28 | 武汉骏安生物科技有限公司 | 一种桑葚发酵原浆及其制备方法和应用 |
CN110179128A (zh) * | 2019-07-15 | 2019-08-30 | 黑龙江省科学院大庆分院 | 一种汉麻籽多肽复方肠溶胶囊及其制备方法 |
-
2022
- 2022-08-19 CN CN202210999821.5A patent/CN115337335A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106924350A (zh) * | 2017-04-07 | 2017-07-07 | 龙文杰 | 一种桑葚提取物及其制备方法和应用 |
CN109939051A (zh) * | 2019-04-25 | 2019-06-28 | 武汉骏安生物科技有限公司 | 一种桑葚发酵原浆及其制备方法和应用 |
CN110179128A (zh) * | 2019-07-15 | 2019-08-30 | 黑龙江省科学院大庆分院 | 一种汉麻籽多肽复方肠溶胶囊及其制备方法 |
Non-Patent Citations (2)
Title |
---|
范智义;李晓琳;李巨秀;: "桑椹提取物中酚类化合物的抗氧化及抗糖基化活性分析", 食品科学, vol. 37, no. 17, pages 19 - 26 * |
郑惠超;: "桑葚花色苷大孔吸附树脂纯化工艺", 农业工程, vol. 6, no. 02, pages 59 - 62 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108887673B (zh) | 富含超氧化物歧化酶sod的野木瓜酵素的制备方法 | |
CN110029034A (zh) | 一种结合糯米糖化发酵的青梅酒及其制备方法 | |
CN107354102B (zh) | 一种耐高糖季也蒙毕赤酵母菌株及其应用 | |
Wu et al. | Mycelial fermentation characteristics and anti-fatigue activities of a Chinese caterpillar fungus, Ophiocordyceps sinensis strain Cs-HK1 (Ascomycetes) | |
Krasnova et al. | Content of phenolic compounds and antioxidant activity in fresh apple, pomace and pomace water extract—Effect of cultivar | |
TWI802194B (zh) | 諾麗果發酵物於製備改善體態及肌膚狀況之組合物之用途 | |
CN114592013A (zh) | 一种蝉花虫草酵素制备方法及其应用 | |
CN115337335A (zh) | 一种具有抗糖化功效的桑葚提取物的制备方法及其应用 | |
TWI704873B (zh) | 用於製備一發酵產物的方法及其所製得的發酵產物暨其應用 | |
TWI602569B (zh) | 微藻多醣萃取物及其萃取方法 | |
KR20000036716A (ko) | 상황버섯 쌀의 제조방법 | |
CN113694106A (zh) | 一种欧李果汁发酵液的制备方法及应用 | |
CN113209193A (zh) | 一种具有抗氧化功能的中药组合物及其应用 | |
CN116211758A (zh) | 一种龙胆提取物及其制备方法和应用 | |
KR20130008823A (ko) | 천연 약재 추출물의 항산화 활성을 향상시키는 방법, 및 이 방법에 의해 수득되는 추출물을 함유하는 노화방지용 화장료 조성물 또는 항산화성 및 항염증성 의약 조성물 | |
CN112708652B (zh) | 一种牛油果水包油液态发酵产品及其制备方法和应用 | |
TWI820566B (zh) | 李子萃取物用於製備提升新陳代謝組合物的用途 | |
CN114317348B (zh) | 一种植物乳杆菌及其应用 | |
CN114948833B (zh) | 可用于化妆品的黄花菜发酵物及其制备方法、应用 | |
TWI744668B (zh) | 由蛹蟲草發酵物提取米蛋白萃取物的生產方法及其應用 | |
ONIAH et al. | Fungi associated with black rot disease of pineapple (Ananas comosus L.) fruits and the effects of the disease on nutritional value of the fruits | |
US20240207347A1 (en) | Methods for inhibiting skin damage, reducing skin sagging, reducing skin porphyrin content, or increasing ferritin content by using queen plum extract | |
CN116725139A (zh) | 一种具有抗氧化、缓解酒精性肝损伤作用的发酵柿子原浆及其制备方法和应用 | |
Yousif | ATHEER SALIH MAHDI | |
Stefanowski et al. | LIPID PEROXIDATION AND CATALASE ACTIVITY IN THE EQUINE BLOOD AFTER IN VITRO TREATMENT WITH EXTRACTS DERIVED FROM STALKS AND ROOTS OF GREATER CELANDINE (CHELIDONIUM MAJUS L.) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221115 |